NVO’s Ozempic Outshines LLY’s Mounjaro in Lowering Cardiovascular Risk
Novo NVO announced new real-world data from the COMPETE SWITCH Cardiovascular (CV) study comparing treatment strategies in adults…
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Medication #cardiovasculardeath #cardiovascularevents #COMPETESWITCHCardiovascular #Health #Mounjaro #novo #Ozempicdose #patients #T2D #ZacksInvestmentResearch
https://www.newsbeep.com/us/866815/